Get the latest news, insights, and market updates on ORIC (ORIC Pharmaceuticals, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on December 1, 2025 (the “Grant Date”), ORIC granted a total of 69,200 non-qualified stock options and 11,400 restricted stock units to three new non-executive employees who began their employment with ORIC in November 2025. These inducement Dec 5, 2025 - $ORIC
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing Dec 5, 2025 - $ORIC
ORIC Pharmaceuticals (ORIC) Valuation Check as New Phase 1b Enozertinib Lung Cancer Data Approaches
ORIC Pharmaceuticals (ORIC) is back on investors’ radar as it prepares to unveil fresh Phase 1b data for its investigational lung cancer therapy enozertinib at the ESMO Asia Congress 2025. See our latest analysis for ORIC Pharmaceuticals. Despite a softer patch recently, with a 30 day share price return of negative 19.07 percent and some profit taking around the latest close at 10.65 dollars, ORIC’s year to date share price return of 28.93 percent and three year total shareholder return of... Dec 3, 2025 - $ORIC
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ETSOUTH SAN FRANCISCO and SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral presentations highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 202 Dec 3, 2025 - $ORIC
ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Poster Presentation in HER2 exon 20 NSCLC at the ESMO Asia Congress 2025
Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ETSOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025 taking place December 5-7, 2025 in Si Dec 1, 2025 - $ORIC
How New ORIC-944 Trial Results and Earnings Update Will Impact ORIC Pharmaceuticals (ORIC) Investors
Earlier this month, ORIC Pharmaceuticals announced new efficacy and safety results from its Phase 1b trial of ORIC-944 in combination with AR inhibitors for patients with metastatic castration-resistant prostate cancer, alongside its third quarter 2025 earnings report showing a net loss of US$32.59 million. The clinical trial results revealed promising prostate-specific antigen (PSA) and circulating tumor DNA (ctDNA) reductions, supporting ongoing dose optimization and potential entry into a... Nov 26, 2025 - $ORIC
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025, at 11:15 a.m. ET. Management will also be participating in one-on-one meetings. The webcast of the fireside Nov 24, 2025 - $ORIC
ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates
Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC’s transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Nov 13, 2025 - $ORIC
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple